Skip to main content
Premium Trial:

Request an Annual Quote

Sensorion, Sonova Partner for €7M Hearing Loss Genotyping Study

NEW YORK – French biotech firm Sensorion and hearing care provider Sonova said on Wednesday that they have signed a multiyear strategic collaboration aimed at establishing genetic analysis in the routine diagnosis of progressive hearing loss in adults.

The deal follows Stäfa, Switzerland-based Sonova’s move in December 2020 to acquire a 3.7 percent stake in Sensorion. At the time, the two companies signed a letter of intent to engage in exclusive negotiations regarding new diagnostic and therapeutic solutions for hearing loss.

Under the new agreement, the firms are conducting a natural history study that will genotype thousands of patients with early onset, severe presbycusis (age-related hearing loss), recruited through Sonova’s Audiological Care stores. The goal is to identify individuals with specific mutations in genes, including GJB2, and to analyze the association of particular mutations with disease severity and progression.

Sonova and Sensorion said they are jointly funding the study with €7.0 million ($8.3 million), split 70/30 between them.

Sensorion CEO Nawal Ouzren said in a statement that the effort will help keep the company "at the cutting edge of hearing loss development by adding to our growing understanding of the ways gene therapy can help fill unmet medical needs beyond childhood and congenital deafness."

The firm's clinical-stage portfolio includes one Phase 2 product, arazasetron, for sudden sensorineural hearing loss. It is also launched three gene therapy programs, currently at the preclinical stage, aimed at correcting hereditary monogenic forms of deafness including deafness caused by a mutation of the gene encoding otoferlin, hearing loss related to gene target GJB2, as well as Usher syndrome type 1.

For its part, Sonova views the study as an opportunity to help advance new modes of screening and treatment, as well as the company's integration into more traditional hearing loss care, CEO Arnd Kaldowski added.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.